Regeneron Pharmaceuticals Revenue and Competitors

Tarrytown, NY USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Regeneron Pharmaceuticals's estimated annual revenue is currently $13.4B per year.(i)
  • Regeneron Pharmaceuticals's estimated revenue per employee is $632,127
  • Regeneron Pharmaceuticals's current valuation is $66.2B. (January 2022)

Employee Data

  • Regeneron Pharmaceuticals has 21135 Employees.(i)
  • Regeneron Pharmaceuticals grew their employee count by 8% last year.

Regeneron Pharmaceuticals's People

NameTitleEmail/Phone
1
Global VP - Supply Chain ManagementReveal Email/Phone
2
SVP, Chief Compliance OfficerReveal Email/Phone
3
VPReveal Email/Phone
4
Sr Manager Founder & Special PopulationsReveal Email/Phone
5
VPReveal Email/Phone
6
VPReveal Email/Phone
7
VPReveal Email/Phone
8
VPReveal Email/Phone
9
SVP and Chief Intellectual Property CounselReveal Email/Phone
10
Chief Staff to SVP. Translational Sciences and OncologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M40%N/AN/A
#2
$3.7M2441%$44MN/A
#3
$6.2M40-7%N/AN/A
#4
$42M271-1%N/AN/A
#5
$12.7M820%$10MN/A
#6
$2.5M160%N/AN/A
#7
$7.5M450%$51.6MN/A
#8
$0.2M1-50%N/AN/A
#9
$4.3M26-16%$3.3MN/A
#10
$3.7M244%N/AN/A
Add Company

What Is Regeneron Pharmaceuticals?

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammation. The Company also has preclinical programs in asthma, allergies, and other diseases and disorders. Regeneron has developed several proprietary platform technologies, which it has incorporated into a comprehensive discovery and development process designed to understand thoroughly the biology of specific disease states, discover potential therapeutic candidates, and evaluate these candidates in clinical trials.

keywords:N/A

N/A

Total Funding

21135

Number of Employees

$13.4B

Revenue (est)

8%

Employee Growth %

$66.2B

Valuation

N/A

Accelerator

Regeneron Pharmaceuticals News

2022-04-20 - Regeneron to Acquire Checkmate Pharmaceuticals and Its ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded...

2022-04-20 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Buy” from Brokerages. Posted by admin on Apr 19th, 2022.

2022-04-20 - Regeneron Pharma To Buy Checkmate Pharmaceuticals In $250 Mln All Cash Deal

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Tuesday its agreement to acquire Checkmate Pharmaceuticals, Inc. (CMPI) at an...

2021-11-17 - Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 Piper Sandler 33rd Annual Healthcare Conference at 8:00 a.m. ...

2021-11-16 - Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 Piper Sandler 33rd Annual Healthcare Conference at 8:00 a.m. ...